The sequencing of the tumor offers new perspectives for the management of lung cancer

The sequencing of the tumor offers new perspectives for the management of lung cancer -

sequencing of tumors in several different lung cancer and surrounding tissue complicates the dominant theory linear progression of lung cancer and offers new perspectives for the management of this deadly cancer, according to a new study from the Mayo Clinic. The sequencing results allow, for the first time, molecular solid evidence of the progress of phenotypic indolent components to more aggressive disease and also show that the two components can move independently, even if they originate from the same precursor, according the study. The paper appears online in Cancer Research .

"This study highlights the potential changes in our understanding of the molecular pathogenesis and better treatment of adenocarcinoma of the lung," said George Vasmatzis, Ph. D., lead author of the study and co -Director of the Biomarker Discovery program at the Mayo Clinic Center for individualized Medicine. "The heterogeneity of lung cancer we repeatedly said that the natural history of tumors and routes of progression vary by case, and several models are possible in certain cancers."

Lung cancer accounts for nearly 0,000 deaths each year in the United States, more than the three most common cancers combined, according to the American Lung Association. The treatment of cancers at an early stage can be adapted to the type of genomic alterations observed explains Dr. Vasmatzis. In some cases, this could mean less: aggressive treatment and observation periods nearby, while other situations may require more immediate interventions, such as surgery or radiation.

"As suggested by clinical studies demonstrating improved disease-free and overall survival for the treatment of lesions containing components of adenocarcinoma in situ [noninvasive lung cancer], it is possible that this represents a distinct clinical entity which can be treated less aggressively or by resection sub-lobar or even watchful waiting periods with almost following up imaging before treatment, "says Dr. Vasmatzis.

future lung cancer genome studies and tumor progression are under the Dr Vasmatzis team in Biomarker Discovery program. Their goal is to develop a series of predictive biomarkers that can help patients and doctors separate cancers potentially aggressive lung and threatening those indolent based molecular signatures found in the patient's tissue.